Man-Chiu Poon

Professor
University of Calgary
Calgary, Alberta, Canada

Presentation(s):

• PB0202 - Long-term effectiveness and safety of emicizumab in people with hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0265 - Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicenter real-world study in China

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0547 - A Canadian Roundtable Discussion of the Peri-operative Use of Nonacog beta pegol (N9-GP) for Persons with Moderate to Severe Hemophilia B

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0613 - Real-World Use of Emicizumab in Chinese Children with Hemophilia A: Retrospective Data from a Comprehensive Care Center

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 61.3 - More cost-effective of intermediate-dose immune tolerance induction regimen for severe hemophilia A children with high-titer inhibitors: the interim report of a randomized multicenter clinical trial

  Tuesday, June 25, 2024
  15:15 – 15:30 ICT